|
Joseph J. Vallner joined Cell Genesys in October 1999 and serves as president and chief operating officer. He currently oversees the research, development, manufacturing, clinical, regulatory and operations departments. Prior to Cell Genesys, he was with SEQUUS Pharmaceuticals for seven years where he was instrumental in the launch of two products including Doxil�, a liposome-based cancer therapeutic. He also helped transition the company through its merger with ALZA Corporation. Prior to SEQUUS, he held various positions with Syntex Corporation and G.D. Searle and Company, and was an associate professor of pharmaceutics at the University of Georgia prior to that. Dr. Vallner, who also serves as a board member of the California Healthcare Institute, received his Ph.D. in pharmaceutics, an M.S. in physical chemistry and a B.S. in pharmacy from the University of Wisconsin, Madison. | 